CycloPen Cyclodialysis System for Open Angle Glaucoma (OAG)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
CREST Site 01, Fort Washington, PA
Open Angle Glaucoma (OAG)+2 More
CycloPen Cyclodialysis System - Device
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

The registry will consecutively enroll adults with open angle glaucoma (OAG) who have undergone intraocular pressure-lowering surgery using the CycloPen System. Data will be retrospectively collected from participants' preoperative ophthalmic examination(s) and the surgical procedure in which the CycloPen System was used. Prospectively, data will be collected from ophthalmic examinations through 24 months postoperatively.

Eligible Conditions

  • Open Angle Glaucoma (OAG)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Open Angle Glaucoma (OAG)

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Baseline, 12 months postoperative

Baseline, 12 months postoperative
Percent of eyes with IOP reduction ≥ 20%

Trial Safety

Safety Progress

1 of 3

Other trials for Open Angle Glaucoma (OAG)

Trial Design

1 Treatment Group

CycloPen
1 of 1
Experimental Treatment

200 Total Participants · 1 Treatment Group

Primary Treatment: CycloPen Cyclodialysis System · No Placebo Group · N/A

CycloPen
Device
Experimental Group · 1 Intervention: CycloPen Cyclodialysis System · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 12 months postoperative
Closest Location: CREST Site 01 · Fort Washington, PA
Photo of pennsylvania 1Photo of pennsylvania 2Photo of pennsylvania 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Open Angle Glaucoma (OAG)
0 CompletedClinical Trials

Who is running the clinical trial?

Iantrek, Inc.Lead Sponsor
Gautam Kamthan, MDStudy DirectorIantrek, Inc.

Eligibility Criteria

Age Any Age · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have used ≤ 3 ocular hypotensive medications prior to surgery.
You have undergone an IOP-lowering surgical procedure using the CycloPen System.
You have an intraocular pressure of less than 31 mmHg prior to surgery.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.